Loading...
•
Sep 30, 2024
Organogenesis Q3 2024 Earnings Report
Reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
Organogenesis Holdings Inc. reported a net revenue of $115.2 million for Q3 2024, a 6% increase compared to Q3 2023. Net income increased by $9.1 million to $12.3 million. The company updated its revenue guidance for the year ending December 31, 2024, expecting net revenue between $455.0 million and $480.0 million.
Net revenue for Q3 2024 was $115.2 million, up 6% year-over-year.
Advanced Wound Care products revenue increased by 7% compared to Q3 2023.
Net income for Q3 2024 increased to $12.3 million, compared to $3.2 million in Q3 2023.
The company expects net revenue between $455.0 million and $480.0 million for the year ending December 31, 2024.
Revenue by Segment
Forward Guidance
The Company is updating its prior revenue guidance and updating its profitability guidance for the year ending December 31, 2024.
Positive Outlook
- Net revenue between $455.0 million and $480.0 million, representing an increase of approximately 5% to 11% year-over-year.
- Net revenue from Advanced Wound Care products between $429.0 million and $452.0 million, an increase of 6% to 11% year-over-year.
Challenges Ahead
- Net loss between $12.3 million and $0.6 million.
- EBITDA between $(1.3) million and $14.4 million.
- Net revenue from Surgical & Sports Medicine products between $26.0 million and $28.0 million, a decrease of 7% to 0% year-over-year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...